Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains

Clostridium Difficile Infection Clinical Trial

Official title:

Prospective Multi-Center Study for Clinical Validation of the Molecular-Based GenePOC CDiff System for the Detection of Toxin B Gene From Toxigenic Clostridium Difficile Strains in Unformed (Soft or Liquid) Human Stool Specimens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02968758
• Other study ID #: GenePOC CDiff_clinical-01
• Status: Completed
• Phase: N/A
• Start date: February 6, 2017
• Est. completion date: August 10, 2017

Study information

• Verified date: January 2019
• Source: Meridian Bioscience, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method considered as gold standard for detection of toxigenic Clostridium difficile in stool specimens.

Description:

The GenePOC CDiff test performed on the GenePOC™ instrument is a qualitative in vitro diagnostic (IVD) test that utilizes automated sample preparation and real-time polymerase chain reaction (rtPCR) to detect the toxin B (tcdB) gene of toxigenic Clostridium difficile (C. difficile) in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI).

The GenePOC CDiff system comprises the GenePOC instrument and the GenePOC CDiff test, which consists of:

1. Transfer Loop (TL)

2. CDiff disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge)

3. CDiff Sample Buffer Tube (SBT)

4. Disposable Transfer Tool (DTT).

The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination.

An unformed (soft or liquid) stool specimen is collected using standard stool collection device. Using a disposable 5µL inoculating loop (transfer loop) dipped into the homogenized stool specimen, stool material is transferred into SBT and vortexed. Sample is then transferred to the GenePOC CDiff PIE. The GenePOC CDiff PIE is then automatically processed by the GenePOC Instrument. On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures.

One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from up to 7 Clinical Centers to obtain a total of 150 specimens positive for CDiff based on the Reference Method final result.

Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2461
• Est. completion date: August 10, 2017
• Est. primary completion date: August 2, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Unformed Stool specimens from patients suspected of having CDI for whom diagnostic tests are indicated and ordered;

• At least 1.25mL of unformed stool specimen (defined as specimen assuming the shape of its container);

• Only one (1) specimen per patient will be included in the study;

• Materials use within their expiration date;

• Transport, storage times, and conditions (e.g. room temperature and/or refrigerated) within requested indications.

Exclusion Criteria:

• Specimens from patients for whom CDI diagnostic tests have not been ordered;

• Transport and storage times and conditions that exceed these Study Protocol requirements;

• Formed or hard stool specimens or rectal swabs.

Related Conditions & MeSH terms

• Clostridium Difficile Infection
• Clostridium Infections

Intervention

Device:
• Comparison between GenePOC PCR and Reference Method
Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.

Locations

Country	Name	City	State
Canada	McGill University Health Centre	Montreal	Quebec
Canada	Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex	Toronto	Ontario
United States	Tricore Laboratory University of New Mexico	Albuquerque	New Mexico
United States	John Hopkins University School of Medicine	Baltimore	Maryland
United States	Detroit Medical Center University Laboratories	Detroit	Michigan
United States	Wishard Health Services	Indianapolis	Indiana
United States	Medical College of Wisconsin	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Meridian Bioscience, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance Characteristics : Clinical Sensitivity (True Positive Rate) and Clinical Specificity (True Negative Rate) in Comparison to the Reference Method	To establish the performance characteristics of the GenePOC CDiff System for its use in determining the presence of CDiff in liquid/unformed stool specimen obtained from patients suspected of having C. difficile infection (CDI).; Sensitivity will be established as the proportion of positives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.; Specificity will be established as the proportion of negatives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.	At the time of the results with Reference Method is confirmed, up to 3 months
Secondary	Positive and Negative Predictive Values (PPV and NPV)	To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC CDiff System.; PPV is the percentage of true positives out of all positive results (true positive/true positive + false positive).; NPV is the percentage of true negatives out of all negative results (true negative/true negative +false negative.).	At the time of the results with Reference Method is confirmed, up to 3 months
Secondary	Unresolved Sample Results	To estimate the rate of unresolved results for the GenePOC CDiff System due to Sample Processing control failure (unresolved sample results).	At the time of the results with Reference Method is confirmed, up to 3 months
Secondary	Indeterminate Sample Results	To estimate the rate of indeterminate results for the GenePOC CDiff Test due to an Instrument failure (indeterminate sample results).	At the time of the results with Reference Method is confirmed, up to 3 months